That is a good question.....I would think with the Epic strategic alliance happening and drugs coming in from Mikah/Actavis that they were hoping to be able to hang onto it, let it continue to grow and not have to monetize their stake. The more I look at it the more all these drug companies are interconnected and helping each other grow. I'm sure Elite would rather not have to sell it and figured the PPS would be much higher at this point but that the multiple FDA holdups and API situation almost forces their hand! Thus, the negatives on the books with the bond debt and in almost dire need for cash for BE studies sort of requires that they look into selling it as soon as possible. Getting the Eli 216 patent when they did may have also led them to look into considering whether they could fund their own trials.
I appreciate they can get a funding deal with Socius but I don't think they are crazy about it. I can appreciate there wouldn't be much dilution with it....but dilution is dilution and I don't feel they need any further. JMO
